|Articles|March 15, 2002
- BioPharm International-03-15-2002
- Volume 15
- Issue 3
Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?
Author(s)Jill Wechsler
by Jill Wechsler, pp. 55-57, 60 The industry must ensure that manufacturing systems can produce high quality and consistent therapies, efforts that may lead to comparable "subsequent entry" products.
Advertisement
Articles in this issue
over 23 years ago
Guest Editorial: Warning Letters ? A Symptom?over 23 years ago
The Importance of Freezing on Lyophilization Cycle Developmentover 23 years ago
Business Benefits of Computer Systems Validationover 23 years ago
A System Developer's Approach to ValidationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
In-Vivo Cell Therapy Model Aims to Reduce Manufacturing Challenges
2
Top 10 Questions from CPHI Frankfurt: Building Pharma Resilience a Common Theme
3
Streamlining Procurement and Inventory Management Leads to Increased Productivity
4
Distribution Resilience: Meeting Global Demand and Delivering Faster, More Reliable Service
5
